Research Studies
|
Clinical trial registration # |
||
|
Trial short name |
||
|
Author (year) |
||
|
Citation |
||
|
Country |
||
|
Study period |
||
|
Study design |
||
|
Study population Characteristics |
||
|
Type of AMD (Dry=1; Wet AMD=2) |
||
|
AMD stage (0=Normal; 1=Early; 2=Intermediate; 3=Late) |
||
|
Total Sample Size of patients (eyes), n |
||
|
Total sample age (years), mean±SD or specified |
||
|
Experimental group |
Intervention therapy |
|
|
# of patients |
||
|
Age (years), mean ± SD |
||
|
Male, n (%) |
||
|
# of patients completed the follow up |
||
|
Control group |
Control therapy |
|
|
# of patients |
||
|
Age (years), mean ± SD |
||
|
Male, n (%) |
||
|
# of patients completed the follow up |
||
|
Follow up time |
||
|
Primary Outcome |
||
|
Efficacy: Vision outcomes |
Best-corrected visual acuity (BCVA), (ETDRS) letters |
|
|
Patients maintained vision (<15-letter loss on the BCVA), in visual loss with n of loss letters on BCVA, or in visual gains with n of the gain letters on the BCVA, % |
||
|
Efficacy: Progression |
Any progression results, n (%) |
|
|
Efficacy: Anatomic outcome
|
Central Retinal Thickness (CRT), central macular thickness (CMT), Central subfield thickness (CS(F)T), or central foveal thickness (CFT), μm |
|
|
Choroidal neovascularization (CNV) area or/and CNV leakage area, total lesion area, mm2 |
||
|
Drusen Volume (Mean±SD or specified), mm3 |
||
|
Presence of intraretinal fluid (IRF), subretinal fluid (SRF), retinal pigment epithelium detachments, or sub-retinal pigmented epithelium (Sub-RPE), n (%) |
||
|
Other |
||
|
Durability Outcome
|
Number of Injection (Mean or specified), n |
|
|
Patients treated frequency during the treat-and-extend period, % |
||
|
Patients treated duration (week or specified) during the treat-and-extend period, % |
||
|
Safety |
Adverse event (AE), n (%) |
|
|
Ocular AE, n (%) |
||
|
Systemic AE , n (%) |
||
|
Serious adverse event, n (%) |
||
|
Treatment discontinuation, n (%) |
||
|
Death, n (%) |
||
|
Treatment-emergent adverse events (TEAEs) |
||
|
Serious treatment-emergent adverse events (TEAEs), n |
||
|
QoL
|
||
|
Resource utility
|
||
|
Pharmacokinetics
|
||
|
Immunogenicity results |
||
|
Conclusion |
||
|
Risk of bias assessment for the primary outcome |
Randomization process |
|
|
Deviations from intended interventions |
||
|
Missing outcome data |
||
|
Measurement of the outcome |
||
|
Selection of the reported result |
||
|
Overall |
||